Therapeutic Outcomes of High Dose-Dexamethasone versus Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim Strategies in Persistent, Chronic, Refractory, and Relapsed Immune Thrombocytopenia Patients.

ABSTRACT:

Background

Primary immune thrombocytopenia (ITP) is an inflammatory autoimmune disease that can be managed with several treatment options. However, there is a lack of comparative data on the efficacy of these options in different phases of the disease.

Aim of the study

This study aimed to evaluate the efficacy of high-dose Dexamethasone (HD-DXM), Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim schedules in persistent, chronic refractory or relapsed Egyptian ITP patients with a platelet count ≤30 × 10⁹/L. The primary outcome measure was a sustained increase in platelet counts over 50 × 10⁹/L for an additional 12 months without additional ITP regimens. The study also aimed to identify a suitable treatment regimen with a long remission

SUBMITTER: Hamed EM 

PROVIDER: S-EPMC10537035 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature